Although prostate cancer is the leading cause of cancer mortality for African men, the 71 vast majority of known disease associations have been detected in European study 72 cohorts. Furthermore, most genome-wide association studies have used genotyping 73 arrays that are hindered by SNP ascertainment bias. To overcome these disparities in 74 genomic medicine, the Men of African Descent and Carcinoma of the Prostate 75 (MADCaP) Network has developed a genotyping array that is optimized for African 76 populations. The MADCaP Array contains more than 1.5 million markers and an 77 imputation backbone that successfully tags over 94% of common genetic variants in 78 African populations. This array also has a high density of markers in genomic regions 79 associated with cancer susceptibility, including 8q24. We assessed the effectiveness of 80 the MADCaP Array by genotyping 399 prostate cancer cases and 403 controls from 81 seven urban study sites in sub-Saharan Africa. We find that samples from Ghana and 82 Nigeria cluster together, while samples from Senegal and South Africa yield distinct 83 ancestry clusters. Using the MADCaP array, we identified cancer-associated loci that 84 have large allele frequency differences across African populations. Polygenic risk 85 scores were also generated for each genome in the MADCaP pilot dataset, and we 86 found that predicted risks of CaP are lower in Senegal and higher in Nigeria. 87 88 Significance: We have developed an Africa-specific genotyping array which enables 89 investigators to identify novel disease associations and to fine-map genetic loci that are 90 associated with prostate and other cancers. 91 542 543 Author's Contributions 544 Conception and design: T.R. Rebbeck, J. Lachance 545 Development of methodology: J. Lachance 546 Acquisition of data (provided animals, acquired and managed patients, provided 547 facilities, etc.): Analysis and interpretation of data (e.g., statistical analysis, biostatistics, 551 computational analysis):
Introduction
Prostate cancer (CaP) is a complex disease that disproportionally affects men of 93 African descent (1). CaP is the leading cause of cancer-related mortality in African men 94 (2). In the United States, African American men have a higher risk of developing CaP, 95 and an even higher increased risk of dying from it compared to men of European or 96 Asian descent (3). In the United Kingdom, men of African descent have an increased 97 risk of being diagnosed and dying from CaP (4). Furthermore, the highest reported 98 mortality rates of CaP are found in the Caribbean men of African descent (5). Multiple 99 socioeconomic, environmental, and genetic factors contribute to this health inequity. 100 Cancer is considered a genetic disease, and CaP has a high heritability: on the 101 order of 58% (6). Risks of CaP tend to run in families; the relative risk of men with 102 affected fathers is 2.1-fold higher compared to men without a family history and the 103 relative risk of men with affected brothers is 2.3-fold higher compared to men without 104 family history (7) . In recent years, multiple genome-wide association studies (GWAS) 105 have detected genetic associations with CaP (8-11). Collectively, these studies have 106 yielded over 200 independent CaP risk-associated loci, and one key genomic region 107 that has been repeatedly implicated in CaP and other cancers is 8q24 (12) (13) (14) . The 108 most comprehensive CaP GWAS analyzed to date included more than 140,000 cases 109 and controls of European ancestry (10). In this study, Schumacher et al. generated a 110 polygenic risk score (PRS) that successfully classified individuals into high and low risk 111 categories. 112 Unfortunately, most GWAS have not focused on populations from sub-Saharan 113 Africa. As of 2016, 81% of all GWAS samples were of European ancestry and 14% of 114 all GWAS samples were of East Asian ancestry (15) . Additionally, existing genotyping 115 arrays do not adequately capture genetic variation in diverse African populations. Both 116 of the aforementioned issues limit what is known about cancer genetics in African 117 populations. Thus, the current set of known disease-associated loci is enriched for 118 alleles with an intermediate frequency in Europe or Asia, but not Africa. This lack of 119 representation can exacerbate existing health disparities by not capturing relevant 120 genetic risk associations in African populations (16, 17) . Disease associations do not 121 Page 6 always replicate across populations and ancestries, and the directions of risk 122 associations at cancer-associated loci may differ across study populations (18, 19) . 123 Previous work also indicates that risks of CaP vary by genetic ancestry across the globe 124 (20, 21) . For example, an earlier GWAS in Ghana showed that the most promising SNP 125 in this African population has not been identified in other populations (22) . Hence, there 126 is a clear need for more studies that analyze the genetics of African populations (23, 24) . 127 Commonly used genotyping arrays tend to use markers that were originally ascertained 128 in European populations (25) . This can cause polygenic risks of complex diseases, 129 including CaP, to be wrongly estimated (26 plots were generated using PLINK and R. ADMIXTURE software (37) was run for K = 2 241 through K = 5. Cross-validation was performed to determine the optimal K value. the Schumacher PRS (r 2 > 0.4). LDlink (41) was then used to select alleles that tag 281 increased CaP risk at proxy markers. Table S2 lists markers that were used to 282 generate the PRS described here. the H3Africa Array. This overlap will facilitate data harmonization and the ability to 319 combine genotype information from different arrays into the same study. 320 We compared the mean derived allele frequencies (DAF) of markers found on the 321 MADCaP, OncoArray, and H3Africa arrays, using Continental allele frequencies from 322 the 1000 Genomes Project (Fig. 2B) and H3Africa Array were lower for African populations than non-African populations 328 (Fig. 2B) . These DAF differences are indicative of SNP ascertainment bias (26). 329 Examining the joint site frequency spectrum of non-African and African populations, 330 similar counts of MADCaP markers are found above and below the diagonal in Fig. 2C . 331 One exception to this pattern is that the MADCaP Array is enriched for markers that are 332 polymorphic in Africa but monomorphic outside of Africa, but not vice-versa. 333 Densities of markers that are found in different genomic regions vary by genotyping 334 array. Here, we focus on 8q24, a cancer-associated genomic region that contains Efficacy of the MADCaP Array 345 We tested the efficacy of the MADCaP Array by genotyping over 800 African 346 individuals from seven MADCaP study sites (Fig. 3A) Population structure and genetic admixture 364 We used two-dimensional multidimensional scaling (MDS) plots to detect population Nigerians. Rotating the MDS plot 85 degrees clockwise reveals that genes mirror 374 geography, at least for the African populations analyzed in our study (Fig. 3D ). 375 Samples from geographically close locations tend to share greater amounts of genetic 376 similarity.
377
ADMIXTURE plots reveal shared ancestry among MADCaP samples (Fig. 3E ). In 378 these plots, individuals are linear mixtures of multiple genetic ancestries -indicated by 379 different colors. Cross-validation error is minimized at K= 3, i.e. the best fit to the data 380 occurs for three ancestry colors (Fig. S1) 396 Genotyping arrays can be used to identify runs of homozygosity -stretches of DNA 397 where maternally and paternally inherited haplotypes are identical. Using the MADCaP 398 array, we quantified cumulative runs of homozygosity (cROH) in each genome (Fig. 4A) . 399 Although there is heterogeneity within each study site, cROH are smaller for South 400 African genomes than Senegalese, Ghanaian, or Nigerian genomes analyzed in this 401 study (p-value = 3.31 x 10 -9 , Wilcoxon rank-sum tests). This lower homozygosity can 402 either be due to large historical population sizes or due to admixture. 403 To distinguish whether this lower homozygosity is due to large historical population 404 sizes or admixture, we calculated LD decay curves for each of the seven MADCaP 405 study sites (Fig. 4B) . Populations with small effective population sizes have more LD 406 than populations with large effective population sizes (43). Admixture also increases 407 the amount of LD (44). In general, we observed less LD for South African sites than 408 other study sites (WITS and SU in Fig. 4B ). These differences in LD decay curves do 409 not appear to be due to admixture, since the South African populations studied here 410 have similar levels of admixture to other African populations (Fig. 3E) . Overall, the data 411 in Fig. 4 support the idea that historic population sizes were larger in South Africa than 412 West Africa. One implication of the smaller haplotype blocks that are found in genomes 413 from Johannesburg and Cape Town is that GWAS using these samples will require traits (e.g., skin pigmentation and smoking). These scores were calculated for three 424 different evolutionary branches: Senegal (Fig. 5A ), Ghana & Nigeria (Fig. 5B) , and 425 South Africa (Fig. 5C) Focusing on CaP-associated loci, we identify loci with large allele frequency 444 differences between populations, as well as loci that have similar allele frequencies for 445 each African population. For example, rs5919432 is a CaP-associated SNP that is 446 located 71kb from the androgen receptor gene at Xq12 (48). This SNP has the highest 447 X-linked PBS score in Fig. 5C . Compared to other study sites, we found that South 448 Africans have elevated frequencies of the risk allele at rs5919432 (Fig. 5D ). These 449 allele frequency differences contribute to population-level differences in CaP-risk. We 450 found that the risk-increasing T allele at rs5919432 is more common in MADCaP cases 451 than controls (34.2% vs. 32.1%). Although the association between rs5919432 and 452 CaP was originally discovered in European men, this data reveals that rs5919432 has a 453 similar effect in African populations. The genomic region 8q24.21 contains multiple loci 454 that have been associated with CaP in European men, including rs6983267 (10). 455 Although rs6983267 at 8q24.21 is associated with CaP, it does not have large allele 456 frequency differences between African populations (Fig. 5E ). We also found that the 457 risk-increasing G allele at rs6983267 is more common in MADCaP cases than controls Sub-Saharan Africa contains substantial amounts of genetic diversity (33, 38, 49) , 507 and this contributes to population-level heterogeneity in cancer risks. For the urban 508 study sites analyzed here, we found that genomes tend to fall into three distinct clusters 509 (Fig. 3C) . These clusters broadly match geography: samples from Senegal display African study sites (Fig. 4) . Clearly, a one-size-fits-all approach is suboptimal when it 515 comes to the genetics of African populations. The genetic heterogeneity of African 516 populations calls for genotyping arrays that accurately capture African polymorphisms. 517 Genetic risks of cancer have changed during recent human history (50) , and our 518 analysis of urban African genomes found many cancer-associated loci that have 519 divergent allele frequencies (Fig. 5 , Table S2 , and Table S3 ). Table S2 . 
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